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The histological counterpart of idiopathic pulmonary ﬁbrosis is usual interstitial pneumonia, in which areas of ﬁbrosis of various
ages are interspersed with normal lung. This pattern could be explained by repeated episodes of lung injury followed by abnormal
wound healing responses. The cause of the initiating alveolar epithelial injury is unknown, but postulated mechanisms include
immunological, microbial, or chemical injury, including aspirated gastric reﬂuxate. Reﬂux is promoted by low basal pressure in
the lower oesophageal sphincter and frequent relaxations, potentiated by hiatus hernia or oesophageal dysmotility. In susceptible
individuals,repeated microaspirationofgastricreﬂuxate maycontribute to the pathogenesisofIPF.Microaspirationofnonacidor
gaseousreﬂuxateispoorlydetected by current testsforgastroesophagealreﬂux which weredeveloped forinvestigatingoesophageal
symptoms. Further studies using pharyngeal pH probes, high-resolution impedance manometry, and measurement of pepsin in
the lung should clarify the impact of reﬂux and microaspiration in the pathogenesis of IPF.
1.Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is the most common
idiopathic interstitial pneumonia and carries a prognosis
worse than many cancers. Despite the progressive and
ultimately fatal nature of this disease, it remains poorly
understood, and there are no eﬀective disease modifying
treatments. Classical hypotheses regarding the pathogenesis
of IPF focused on a chronic inﬂammatory model leading to
ﬁbrosis, but the resulting treatment strategies focusing on
anti-inﬂammatory agents have proven largely ineﬀective in
altering the disease course and mortality [1–3]. Over recent
years, our understanding of this condition has moved away
from the inﬂammatory model towards a hypothesis focusing
on alveolar epithelial injury followed by abnormal tissue
repair and aberrant wound healing [4]. This model proposes
that failure of normal re-epithelialisation following loss of
alveolar-capillary basement membrane secondary to lung
injury results in cytokine-mediated ﬁbroblast proliferation
and subsequent ﬁbrosis. Therefore, it is suggested that
development of this disease requires underlying suscepti-
bility combined with exposure to a source of lung injury.
Much work has been done exploring genetic susceptibility
to IPF, prompted by the recognition of families aﬀected by
pulmonary ﬁbrosis [5]. Numerous genetic polymorphisms
have been studied including the major histocompatibility
complexes [6], tumour necrosis factor-α [7], Fcgamma
receptors [8, 9], and telomerase [10], and positive associ-
ations with IPF have been demonstrated. Short telomeres
and telomerase mutations, which may compromise cell
renewal capacity in tissues, have been demonstrated in
peripheral blood leukocytes in some IPF families and in a
subset of sporadic IPF cases [11]. These ﬁndings suggest
that IPF may be a disorder of lung regeneration, and
although none of these factors have been found to be either
necessary or suﬃcient to cause the disease in isolation,
pulmonary ﬁbrosis may ensue only in response to certain
stimuli.
Understanding the source of initial lung injury is central
to understanding IPF. Proposed injurious agents include2 Pulmonary Medicine
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Figure 1: “Epithelial hypothesis”: proposed mechanisms of alveolar epithelial injury and ﬁbrosis in IPF.
viruses [12, 13], autoantibodies [14], and chemicals includ-
ingthereﬂuxandaspirationofacidornonacidmaterialfrom
the gastrointestinal tract (Figure 1).
2.Pathophysiologyof AbnormalReﬂux
Abnormal Gastroesophageal reﬂux occurs when there is
failure of one or more of the physiological protective
mechanisms. The reﬂux of gastric contents in health is
prevented through the combined actions of the oesophageal
musculature including the lower oesophageal sphincter
(LES) that must maintain a normal tone and frequency of
transient relaxations and the diaphragmatic crura providing
an extrinsic pressure. Phonation alters the anatomy of the
crural diaphragm and immediately predisposes to reﬂux
in humans. Disorders aﬀecting the LES can be functional
(increased frequency of transient relaxations) or mechanical
(reduced LES tone) and can be caused by a number of
factors including hiatus hernia, certain foods, and drugs.
Cigarette smoking results in reversible relaxation of thelower
oesophageal sphincter with an early study demonstrating
that two-thirdsofcigarettes smokedresult ina reﬂux episode
in symptomatic individuals [15, 16]. Cigarette smoking is
associated with an increased risk of developing idiopathic
pulmonary ﬁbrosis, with a negative impact onprognosis, but
t h en a t u r eo ft h i sr e l a t i o n s h i pa n dt h er o l eo fr e ﬂ u xh a sn o t
been explored [17].
An additional factor inﬂuencing Gastroesophageal reﬂux
is the pressure gradient between the abdomen and the tho-
rax. It is suggested that the increased negative intrathoracicPulmonary Medicine 3
pressure associated with diseases that reduce lung compli-
ance may predispose to reﬂux [18, 19]. Gastric reﬂuxate
may be liquid, gaseous, or particulate; acid or nonacid;
distal (localized to the distal oesophagus) or proximal
(reaching the proximal oesophagus and pharynx) [20, 21].
Heartburn as a symptom of liquid acid reﬂux in the distal
oesophagus is common in the general population [22, 23].
However,a signiﬁcantproportionofGastroesophageal reﬂux
is asymptomatic [24] and may indeed be underestimated
in the many studies that have used only pH monitoring,
which fails to detect nonacid reﬂux. Potentially injurious
agents in nonacid or weak-acid reﬂuxate include bile salts
and enzymes including pepsin. Studies of reﬂux in patients
with laryngeal and respiratory symptoms have shown that
the concept of reﬂux being synonymous with heartburn
is outdated. Proximal reﬂux is strongly associated with
laryngeal symptoms such as dysphonia, hoarseness, and
throat clearing. Abnormal oesophageal peristalsis may be
an important contributor to extra-esophageal symptoms of
reﬂux by prolonging esophageal acid clearance time (i.e.,
reﬂuxate remains in the proximal oesophagus for longer
time) [25]. It is increasingly recognised that gaseous or
particulate proximal acid or nonacid reﬂux is associated
with a variety of respiratory conditions including chronic
cough [26, 27], asthma, COPD, and bronchiectasis [28, 29].
Detection of pepsin and bile salts in bronchoalveolar lavage
(BAL) ﬂuid provides unequivocal evidence of aspiration of
reﬂuxate into the lower respiratory tract, which is referred to
as microaspiration in the absence of a classical major clinical
aspiration event [30]. The association of Gastroesophageal
reﬂux with ﬁbrotic lung disease has historical roots [31–33]
althoughaprecisetemporalrelationship betweenpulmonary
ﬁbrosis and reﬂux has not been established and there is
uncertaintyovercauseoreﬀect.However,thehypothesisthat
repeated microaspiration of aerosolised particles secondary
to Gastroesophageal reﬂux leads to alveolar epithelial injury,
and subsequent ﬁbrosis is attractive and is worthy of further
investigation.
3.Studiesof GastroesophagealReﬂuxand IPF
The notion of recurrent microaspiration as a potential cause
of pulmonary ﬁbrosis is an old one, with reported case series
datingbackoverhalfa century[31],butclinicalstudiescame
later with the advent of oesophageal physiology technology.
In 1979, Pellegrini and colleagues [34] published a study of
100 patients with reﬂux investigated by pH monitoring and
found that patients with oesophageal hypomotility and weak
peristalsis were more likely to have respiratory symptoms.
There was a limited correlation between typical oesophageal
reﬂux symptoms (e.g., heartburn) and objective reﬂux
events. A number of studies have subsequently attempted to
evaluate the exact prevalence of reﬂux in IPF (Table 1).
In a prospective study of 17 consecutive IPF patients,
Tobin and colleagues [35] found a signiﬁcantly higher
prevalence of oesophageal acid reﬂux (detected by ambu-
latory pH monitoring) in the IPF group. Most patients
with IPF and abnormal oesophageal acid exposure did
not have typical oesophageal reﬂux symptoms such as
heartburn or regurgitation. In this small study, there was no
signiﬁcant correlation between lung function (DLCO) and
acid exposure times.
Raghu et al. [36] conducted the largest prospective study
of IPF patients to date to determine the prevalence and
characteristics of GER in this population. Sixty-ﬁve IPF
patients were evaluated in this study and compared with 133
patients with intractable asthma. There was a signiﬁcantly
higher prevalence of reﬂux in the IPF group, but there
was no signiﬁcant correlation between the severity of IPF
and the percentage of proximal and distal oesophageal acid
reﬂux time. Only 47% of the IPF patients had typical reﬂux
symptoms of heartburn or regurgitation. Furthermore, 65%
ofpatientsweretakingaprotonpumpinhibitoratthetimeof
the study suggesting that 87% prevalence of reﬂux might be
an underestimate. On the basis of these ﬁndings, the authors
suggested that investigation with oesophageal pH testing was
indicated for IPF patients irrespective of symptoms of acid
reﬂux.
In a prospective study of 28 consecutive patients with
IPF, Bandeira and colleagues [38] evaluated the prevalence
of Gastroesophageal reﬂux disease (GERD) by oesophageal
manometry andpHstudiesanddividedthestudypopulation
into GERD+ and GERD− groups. In GERD+ group,
77% had heartburn or regurgitation in comparison to 33%
in the GERD− group, supporting the suggestion that
oesophageal symptoms alone are inadequate markers of
GER. In terms of oesophageal motility studies, the most
common ﬁndings were ofoesophageal hypomotilityand LES
hypotonia. There was no signiﬁcant diﬀerence in clinical or
functional characteristics (includingFEV1,FVC,and DLCO)
between the GERD+ and GERD− groups.
The association of reﬂux with parenchymal lung dis-
ease has also been evaluated in connective tissue disease-
associatedpulmonaryﬁbrosis,andinparticularscleroderma.
In a prospective study of 40 consecutive patients with
scleroderma [39], there were signiﬁcantly higher number of
acid and nonacid reﬂux episodes in patients with interstitial
lung disease compared to patients with normal thoracic
high-resolution computed tomography (HRCT) scans. Fur-
thermore, there was a good correlation between pulmonary
ﬁbrosis scores and reﬂux events at both the proximal and
distal oesophagus.
There is a high prevalence of Gastroesophageal reﬂux
in IPF patients referred for lung transplantation. Sixty-
seven percent of patients had Gastroesophageal reﬂux in a
cohort of 30 patients in a study by Sweet and colleagues
[40]. Moreover, 65% of those with reﬂux had a hypotensive
L E S .T h ep r e s e n c eo ft y p i c a lr e ﬂ u xs y m p t o m so fh e a r t b u r n ,
regurgitation, or dysphagia had limited sensitivity and
speciﬁcity for the detection of distal oesophageal reﬂux,
supporting the suggestion that oesophageal symptoms are a
poorscreening tooltodetectabnormalreﬂuxin IPFpatients,
and the threshold to consider underlying reﬂux disease in
this population should be low.
The role of reﬂux and microaspiration in the patho-
genesis of lung disease is strengthened by a retrospective
analysis of 457 patients undergoing lung transplantation4 Pulmonary Medicine
Table 1: Prominent clinical studies evaluating gastroesophageal reﬂux in IPF.
Study Methodology Number of subjects Prevalence of GERD Other outcomes
Tobin et al. 1998
[35]
Prospective with
non-IPF ILD control
17 IPF
8 controls
94% IPF
50% controls
25% of IPF patients had typical reﬂux
symptoms
Raghu et al. 2006
[36]
Prospective, control
group without ILD
65 IPF
133 asthmatics
87% IPF
68% Asthma
47% of IPF patients had heartburn and
regurgitation. No signiﬁcant diﬀerence in
proximal reﬂux in IPF and asthma, 63%
versus 61%, respectively
Raghu et al. 2006
[19]
Retrospective case
review 4I P F 100% as one of the
inclusion criteria
2–6 year follow up with stable FVC and
TLCO with proton pump inhibitors
Salvioli et al. 2006
[37] Prospective
18 IPF
10 secondary
pulmonary ﬁbrosis
67% of IPF patients had
abnormaldistal reﬂux
57% of total patients had heartburn and
regurgitation
Bandiera et al.
2009 [38] Prospective 28 IPF 35.7% Participants divided into GRED+ and
GERD− groups
[41]. The study population was stratiﬁed into four groups
on the basis of history of typicalreﬂux symptoms and timing
of fundoplication. The group of patients who underwent
fundoplicationpriortolungtransplant orshortlyaftertrans-
plant had a lower incidence of acute rejection/bronchiolitis
obliterans syndrome (BOS) and better survival than the
group which did not undergo antireﬂux surgery. This study
has led to suggestions that microaspiration of stomach
contents may play an important role in the pathophysiology
of posttransplant BOS, and gastric reﬂuxate could be an
inciting trigger for transplant rejection.
These studies support the notion that GER is associated
w i t hI P F .H o w e v e r ,G E R Di sc o m m o ni nt h eg e n e r a l
population (10%–20% in the Western World) and up to
50 reﬂux events per 24 hours is considered normal, so
it is not possible to draw a ﬁrm conclusion regarding a
cause-and-eﬀect relationship. Conceivably, reﬂux could be a
secondary event in patients with IPF because of mechanical
eﬀects. Advanced ﬁbrosis is associated with decreased lung
compliance and increased negative pleural pressure, thus
potentially promoting reﬂux of gastric contents into the
oesophagus [19].
4.Pathophysiologyand Histologyof
LungInjury
We and others [42–44] have found that histopathological
analysis may support a diagnosis of reﬂux and aspiration in
selected cases of pulmonary parenchymal injury. A distinct
histological pattern of “centrilobular ﬁbrosis” has been
describedthat is possibly associated with GER andaspiration
[44]. This may be observed in patients with scleroderma,
who are especially prone to GER and aspiration due to
oesophageal involvement in their disease. The presence of
foreign material in a lung biopsy specimen along with
a pattern of centrilobular ﬁbrosis is highly suggestive of
aspiration-induced lung injury.
Another distinct clinicopathological entity associated
with centrilobular and peribronchiolar ﬁbrosis is bronchi-
olocentric interstitial pneumonia. Yousem and Dacic [45]
reported 10 cases of this interstitial lung disease with patchy
lymphocytic alveolitis without granuloma formation. It can
be speculated that Gastroesophageal reﬂux may play a role
in the development of this distinct interstitial lung disease as
aspirated material from gastro and extra-esophageal reﬂux
would have a propensity to cause interstitial pneumonia in a
centrilobular and peribronchiolar distribution.
Whilst lower oesophageal liquid acid reﬂux leading to
heartburn is associated with respiratory disease including
IPF in epidemiological studies, it is more diﬃcult to detect
proximal gaseous reﬂux that is likely to be aspirated into
the airways and alveoli. This type of reﬂux may elicit
symptoms of hoarseness, throat clearing, cough, wheeze,
and breathlessness, and the threshold for manifesting these
symptoms depends on neural sensitivity of the larynx and
airways [46] .T h ep r e c i s ei n j u r i o u sa g e n t si nr e ﬂ u x a t eh a v e
not been characterized in detail but may include enzymes
and bile salts. Nonetheless, the airways and alveoli would
seem to be poorly designed to resist the noxious reﬂuxate
once it has traversed past the larynx. At present, we can only
speculate about why some patients would respond to airway
microaspiration with cough or wheeze, whereas in others,
the reﬂuxate is transported to the distal airspaces, where
it may induce alveolar epithelial injury or apoptosis. These
questions are worthy of further investigation.
5.AcuteExacerbationsofIPF and
Gastro-EsophagealReﬂux
The natural history of IPF is variable. Some individuals
exhibit periods of relatively stable lung function followed by
acute deterioration in respiratory function with no obvious
cause [47], which is referred to as an acute exacerbation
of IPF (AE-IPF). A number of studies have reported this
clinical entity which is associated with high mortality (20%–
86%) [48–50]. The most common histological pattern seen
in AE-IPF is diﬀuse alveolar damage superimposed on UIP
pattern [51–53], although organizing pneumonia has also
been reported [48]. The etiology of these exacerbations is
unknown, and one of several hypotheses suggested for AE-
IPF is Gastroesophageal reﬂux and aspiration [54].Pulmonary Medicine 5
6.Investigationsand Treatment
A clinical suspicion of reﬂux and microaspiration should
not rely on oesophageal symptoms of heartburn and regur-
gitation but will be increased if cough is a prominent
symptom, especially if it occurs on phonation or is related
to certain foods or meals or occurs on rising from bed
(when the LES relaxes) [55]. Further investigations are often
unhelpful—for example, upper gastrointestinal endoscopy
is often grossly normal. Our practice with IPF patients is
to institute an empiric trial of medical treatment if clinical
suspicion of reﬂux is high, particularly if the patient reports
a chronic cough. It should be accepted, however, that good
quality clinical trial evidence is lacking, even in studies of
patients with chronic cough in the absence of lung disease.
In patients who report heartburn, we prescribe high-dose
proton pump inhibitor therapy (e.g., lansoprazole 30mg
twicedaily),andforpatientswithoutheartburn,weprescribe
a gastric motility agent (e.g., domperidone 10mg three
times daily), in combination with dietary and behavioural
advice. Ambulatory oesophageal pH monitoring fails to
detect nonacid reﬂux, but concurrent impedance manom-
etry can be used to investigate esophageal peristalsis. Some
patientswithreﬂuxandmicroaspiration regurgitatefromthe
proximal esophagus before the food reaches the stomach,
and this predicts a poor response to antireﬂux therapy.
Surgical fundoplication eﬀectively treats acid and nonacid
reﬂuxinthemajorityofpatients—itseﬀectivenessintreating
resistant heartburn or regurgitation is well proven, but its
utility for extra-esophageal reﬂux symptoms is currently the
focus of much investigation in a variety of settings [56].
Antireﬂux surgery should be considered in patients resistant
to conventional medical therapy. There is evidence of a
positive impact of antireﬂux surgery on exercise capacity
and oxygen requirements in patients with IPF awaiting lung
transplantation. Linden and colleagues [57] evaluated 149
patients on a lung transplant waiting list. Fourteen patients
with IPF had signiﬁcant reﬂux detected by oesophageal
pH monitoring and symptom analysis despite being on
medicaltherapywithprotonpumpinhibitors.Thesepatients
had a signiﬁcant improvement in exercise capacity and
need for supplementary oxygen following antireﬂux surgery.
The laparoscopic route of fundoplication to treat gastroe-
sophageal reﬂux has the advantage of reduced morbidity
and shorter hospital stays compared with conventional open
surgery. We believe the threshold for recommending this
procedure in drug-resistant reﬂux manifesting as either
oesophageal or extra-esophageal symptoms should be low in
IPF patients.
7.FutureDevelopments
The minimally invasive pharyngeal pH probe, which detects
liquid as well as aerosolized acid, is inserted transnasally and
rests just behind the soft palate for between 24 and 48 hours,
and data is transmitted by wireless telemetry to a recorder
(Restech Dx-pH measurement system, Respiratory Technol-
ogy Corporation, San Diego, CA, USA). In our department,
the pharyngeal probe has detected acid reﬂux in the upper
airway in a series of patients in whom oesophageal pH
monitoring failed to detect any signiﬁcant Gastroesophageal
acid reﬂux [58]. High-resolution impedance manometry
is another new technique that should better characterize
nonacid reﬂux. A series of 36 sensors distributed at 1cm
intervals along the length of the oesophageal probe permit
simultaneous pressure measurements, particularly regarding
the individual components of the antireﬂux barrier compris-
ing the lower oesophageal sphincter and the diaphragmatic
crura. Finally, detection of the gastric enzyme pepsin in
exhaled breath, induced sputum, or BAL has been used
successfully forinvestigating aspiration episodes. These tech-
niquesneedtobeappliedincombinationtobetterdetermine
the temporal relationships between reﬂux and development
and progression of IPF in a large population of patients.
8.Conclusion
There is a need for further investigation into the association
o fG E Ra n dI P Fi na na t t e m p tt os u b s t a n t i a t ea n yc a u s a l
link since GER could predispose to or directly incite alveolar
epithelial injury leading to parenchymal ﬁbrosis. It will
be important to investigate nonacid and gaseous reﬂux
in greater detail utilizing both subjective and objective
measures.
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